International Conference Features UCSF Breast Cancer Experts
UCSF breast cancer experts will present new research and clinical findings at the annual San Antonio Breast Cancer Symposium, the largest and most prestigious breast cancer conference.

University of California San Francisco
Give to UCSFUCSF breast cancer experts will present new research and clinical findings at the annual San Antonio Breast Cancer Symposium, the largest and most prestigious breast cancer conference.
A new UCSF study reports for the first time that significant hearing issues often occur among adult survivors of the most common forms of cancer.
For many women, breast cancer screening with a three-dimensional imaging technique called digital breast tomosynthesis (DBT) may not offer advantages over digital mammography, but for some it may reduce the chance of an advanced cancer diagnosis, according to a new JAMA study.
UCSF research scientists and statisticians have developed improved biomarker classifications as part of their research results in the I-SPY 2 trial for high-risk breast cancer patients. The new cancer response subtypes reflect responsiveness to drug treatments and are intended to help clinicians be more precise in how they target therapies.
The latest advances in cancer care and research will be showcased at the annual American Society of Clinical Oncology (ASCO) Annual Meeting, the world’s largest clinical cancer meeting.
Mark Moasser, MD, has sorted out why HER2, the protein driving 1 in 5 breast cancers, is so hard to drug. He explains how the findings correct a naive way of envisioning how HER2 is shaped and how it works.
Helen Diller Family Cancer Research BuildingExperts from UCSF Health will present new research and clinical findings at the annual San Antonio Breast Cancer Symposium, the world’s largest and most
Researchers at UCSF and UC San Diego have mapped out how hundreds of mutations involved in two types of cancer affect the activity of proteins that are the ultimate actors behind the disease.
Researchers at UCSF have gained insight into how cancer cells proliferate despite a myriad of stresses.
What kills most people who die from cancer is not the initial tumor. It’s the intolerable disease burden on the body that arises when tumor cells continually expand their numbers after spreading to different organs.
A new, $9 million grant from the National Cancer Institute to increase ethnic diversity will help the study work toward a goal of enrolling 100,000 or more women overall.
A new model of the causes of breast cancer, created by a team led by researchers at UCSF, Genentech and Stanford University, is designed to capture the complex interrelationships between dozens of primary and secondary breast cancer causes and stimulate further research.
In a breakthrough with important implications for the future of immunotherapy for breast cancer, UCSF scientists have found that blocking the activity of a single enzyme can prevent a common type of breast cancer from spreading to distant organs.
A new web tool spells out for the first time the exposures that more than 6.5 million working women in California face that could increase their risk for breast cancer, including industrial solvents, antimicrobials and phthalates.
UC San Francisco scientists have designed a large-scale screen that efficiently identifies drugs that are potent cancer-killers when combined, but only weakly effective when used alone. Using this
UCSF demonstrates that cancer is a clever engineer, capable of constructing entirely new disease-promoting networks out of raw materials readily available in the cell.
UCSF researchers found that 58 percent of women who resided in a nursing home for more than 90 days before breast cancer surgery experienced significant functional decline one year after surgery.
Follow-up imaging for women with non-metastatic breast cancer varies widely across the country, according to a new study led by researchers at UCSF.
Researchers identified a protein that cancer cells use as a shield to protect the PI3K pathway against targeted drugs, and showed that blocking this protein allowed previously ineffective therapies to slow cancer cell growth and shrink tumors.
Automated breast-density evaluation was just as accurate in predicting women’s risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists.
New study could make it much easier for physicians to use the genetic profile of a patient’s tumor to pick the chemotherapy treatment with the fewest side effects and best chance of success.
More and more, the promise of EHRs transforming data into knowledge is beginning to bear fruit.
UCSF: The Campaign is taking on the world’s most complex health challenges, powered by an exceptional community of mavericks, innovators, and advocates. Together we will make the Bay Area and our world healthier for all.
Women who receive a breast cancer diagnosis while they are still young enough to bear children can take time to freeze their eggs and embryos without fear of delaying their cancer treatment.
A molecular test can pinpoint which patients will have a very low risk of death from breast cancer even 20 years after diagnosis and tumor removal, according to a new clinical study led by UCSF in collaboration with colleagues in Sweden.